Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-oncology Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Drugs Market Perspective (2018-2029)
2.2 Immuno-oncology Drugs Growth Trends by Region
2.2.1 Global Immuno-oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Immuno-oncology Drugs Historic Market Size by Region (2018-2024)
2.2.3 Immuno-oncology Drugs Forecasted Market Size by Region (2024-2029)
2.3 Immuno-oncology Drugs Market Dynamics
2.3.1 Immuno-oncology Drugs Industry Trends
2.3.2 Immuno-oncology Drugs Market Drivers
2.3.3 Immuno-oncology Drugs Market Challenges
2.3.4 Immuno-oncology Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immuno-oncology Drugs Players by Revenue
3.1.1 Global Top Immuno-oncology Drugs Players by Revenue (2018-2024)
3.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2018-2024)
3.2 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immuno-oncology Drugs Revenue
3.4 Global Immuno-oncology Drugs Market Concentration Ratio
3.4.1 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2022
3.5 Immuno-oncology Drugs Key Players Head office and Area Served
3.6 Key Players Immuno-oncology Drugs Product Solution and Service
3.7 Date of Enter into Immuno-oncology Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Drugs Breakdown Data by Type
4.1 Global Immuno-oncology Drugs Historic Market Size by Type (2018-2024)
4.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2024-2029)
5 Immuno-oncology Drugs Breakdown Data by Application
5.1 Global Immuno-oncology Drugs Historic Market Size by Application (2018-2024)
5.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Immuno-oncology Drugs Market Size (2018-2029)
6.2 North America Immuno-oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Immuno-oncology Drugs Market Size by Country (2018-2024)
6.4 North America Immuno-oncology Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Market Size (2018-2029)
7.2 Europe Immuno-oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Immuno-oncology Drugs Market Size by Country (2018-2024)
7.4 Europe Immuno-oncology Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Drugs Market Size (2018-2029)
8.2 Asia-Pacific Immuno-oncology Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2018-2024)
8.4 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immuno-oncology Drugs Market Size (2018-2029)
9.2 Latin America Immuno-oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Immuno-oncology Drugs Market Size by Country (2018-2024)
9.4 Latin America Immuno-oncology Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Drugs Market Size (2018-2029)
10.2 Middle East & Africa Immuno-oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2018-2024)
10.4 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Detail
11.1.2 Amgen, Inc Business Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Introduction
11.1.4 Amgen, Inc Revenue in Immuno-oncology Drugs Business (2018-2024)
11.1.5 Amgen, Inc Recent Development
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Detail
11.2.2 AstraZeneca, Plc Business Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Introduction
11.2.4 AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2018-2024)
11.2.5 AstraZeneca, Plc Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2018-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Detail
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Introduction
11.4.4 Celgene Corporation Revenue in Immuno-oncology Drugs Business (2018-2024)
11.4.5 Celgene Corporation Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Introduction
11.5.4 Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2018-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.6.5 Merck & Co. Recent Development
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Company Detail
11.7.2 Hoffmann-La Roche AG Business Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Introduction
11.7.4 Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2018-2024)
11.7.5 Hoffmann-La Roche AG Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2018-2024)
11.8.5 Johnson & Johnson Recent Development
11.9 Novartis International AG
11.9.1 Novartis International AG Company Detail
11.9.2 Novartis International AG Business Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Introduction
11.9.4 Novartis International AG Revenue in Immuno-oncology Drugs Business (2018-2024)
11.9.5 Novartis International AG Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Detail
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Introduction
11.10.4 AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.10.5 AbbVie, Inc. Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Detail
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Introduction
11.11.4 Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.11.5 Pfizer Inc. Recent Development
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Detail
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Introduction
11.12.4 Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.12.5 Sanofi S.A. Recent Development
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Company Detail
11.13.2 EMD Serono, Inc. Business Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Introduction
11.13.4 EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.13.5 EMD Serono, Inc. Recent Development
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Company Detail
11.14.2 Gilead Sciences Inc. Business Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Introduction
11.14.4 Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.14.5 Gilead Sciences Inc. Recent Development
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Company Detail
11.15.2 Prometheus Therapeutics & Diagnostics Business Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Introduction
11.15.4 Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.15.5 Prometheus Therapeutics & Diagnostics Recent Development
11.16 Aduro BioTech
11.16.1 Aduro BioTech Company Detail
11.16.2 Aduro BioTech Business Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Introduction
11.16.4 Aduro BioTech Revenue in Immuno-oncology Drugs Business (2018-2024)
11.16.5 Aduro BioTech Recent Development
11.17 Galena Biopharma
11.17.1 Galena Biopharma Company Detail
11.17.2 Galena Biopharma Business Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Introduction
11.17.4 Galena Biopharma Revenue in Immuno-oncology Drugs Business (2018-2024)
11.17.5 Galena Biopharma Recent Development
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Company Detail
11.18.2 Bavarian Nordic Business Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Introduction
11.18.4 Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2018-2024)
11.18.5 Bavarian Nordic Recent Development
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Company Detail
11.19.2 Celldex Therapeutics Business Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Introduction
11.19.4 Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.19.5 Celldex Therapeutics Recent Development
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Company Detail
11.20.2 ImmunoCellular Therapeutics Business Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Introduction
11.20.4 ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.20.5 ImmunoCellular Therapeutics Recent Development
11.21 Incyte
11.21.1 Incyte Company Detail
11.21.2 Incyte Business Overview
11.21.3 Incyte Immuno-oncology Drugs Introduction
11.21.4 Incyte Revenue in Immuno-oncology Drugs Business (2018-2024)
11.21.5 Incyte Recent Development
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Company Detail
11.22.2 Dendreon Corporation Business Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Introduction
11.22.4 Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2018-2024)
11.22.5 Dendreon Corporation Recent Development
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Company Detail
11.23.2 Agilent Technologies Inc. Business Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Introduction
11.23.4 Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.23.5 Agilent Technologies Inc. Recent Development
11.24 Agenus Inc.
11.24.1 Agenus Inc. Company Detail
11.24.2 Agenus Inc. Business Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Introduction
11.24.4 Agenus Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.24.5 Agenus Inc. Recent Development
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Company Detail
11.25.2 Enzo Biochem, Inc. Business Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Introduction
11.25.4 Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.25.5 Enzo Biochem, Inc. Recent Development
11.26 Lonza Group
11.26.1 Lonza Group Company Detail
11.26.2 Lonza Group Business Overview
11.26.3 Lonza Group Immuno-oncology Drugs Introduction
11.26.4 Lonza Group Revenue in Immuno-oncology Drugs Business (2018-2024)
11.26.5 Lonza Group Recent Development
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Company Detail
11.27.2 Bio-Rad Laboratories, Inc. Business Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Introduction
11.27.4 Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.27.5 Bio-Rad Laboratories, Inc. Recent Development
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Company Detail
11.28.2 Avantor, Inc. Business Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Introduction
11.28.4 Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.28.5 Avantor, Inc. Recent Development
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Company Detail
11.29.2 Spring Bank Pharmaceuticals, Inc. Business Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Introduction
11.29.4 Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Company Detail
11.30.2 Ferring Pharmaceuticals Business Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Introduction
11.30.4 Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2018-2024)
11.30.5 Ferring Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Immune System Modulators
Table 4. Key Players of Cancer Vaccines
Table 5. Key Players of Oncolytic Virus
Table 6. Key Players of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Immuno-oncology Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Immuno-oncology Drugs Market Share by Region (2018-2024)
Table 11. Global Immuno-oncology Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Market Share by Region (2024-2029)
Table 13. Immuno-oncology Drugs Market Trends
Table 14. Immuno-oncology Drugs Market Drivers
Table 15. Immuno-oncology Drugs Market Challenges
Table 16. Immuno-oncology Drugs Market Restraints
Table 17. Global Immuno-oncology Drugs Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Immuno-oncology Drugs Market Share by Players (2018-2024)
Table 19. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
Table 20. Ranking of Global Top Immuno-oncology Drugs Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Immuno-oncology Drugs Revenue (CR5 and HHI) & (2018-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Immuno-oncology Drugs Product Solution and Service
Table 24. Date of Enter into Immuno-oncology Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2024)
Table 28. Global Immuno-oncology Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Immuno-oncology Drugs Revenue Market Share by Type (2024-2029)
Table 30. Global Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Immuno-oncology Drugs Revenue Market Share by Application (2018-2024)
Table 32. Global Immuno-oncology Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Immuno-oncology Drugs Revenue Market Share by Application (2024-2029)
Table 34. North America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 36. North America Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 39. Europe Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 42. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 45. Latin America Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 48. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 49. Amgen, Inc Company Detail
Table 50. Amgen, Inc Business Overview
Table 51. Amgen, Inc Immuno-oncology Drugs Product
Table 52. Amgen, Inc Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 53. Amgen, Inc Recent Development
Table 54. AstraZeneca, Plc Company Detail
Table 55. AstraZeneca, Plc Business Overview
Table 56. AstraZeneca, Plc Immuno-oncology Drugs Product
Table 57. AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 58. AstraZeneca, Plc Recent Development
Table 59. Bristol-Myers Squibb Company Detail
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Immuno-oncology Drugs Product
Table 62. Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. Celgene Corporation Company Detail
Table 65. Celgene Corporation Business Overview
Table 66. Celgene Corporation Immuno-oncology Drugs Product
Table 67. Celgene Corporation Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 68. Celgene Corporation Recent Development
Table 69. Eli Lilly and Company Company Detail
Table 70. Eli Lilly and Company Business Overview
Table 71. Eli Lilly and Company Immuno-oncology Drugs Product
Table 72. Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 73. Eli Lilly and Company Recent Development
Table 74. Merck & Co. Company Detail
Table 75. Merck & Co. Business Overview
Table 76. Merck & Co. Immuno-oncology Drugs Product
Table 77. Merck & Co. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 78. Merck & Co. Recent Development
Table 79. Hoffmann-La Roche AG Company Detail
Table 80. Hoffmann-La Roche AG Business Overview
Table 81. Hoffmann-La Roche AG Immuno-oncology Drugs Product
Table 82. Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 83. Hoffmann-La Roche AG Recent Development
Table 84. Johnson & Johnson Company Detail
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Immuno-oncology Drugs Product
Table 87. Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Novartis International AG Company Detail
Table 90. Novartis International AG Business Overview
Table 91. Novartis International AG Immuno-oncology Drugs Product
Table 92. Novartis International AG Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 93. Novartis International AG Recent Development
Table 94. AbbVie, Inc. Company Detail
Table 95. AbbVie, Inc. Business Overview
Table 96. AbbVie, Inc. Immuno-oncology Drugs Product
Table 97. AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 98. AbbVie, Inc. Recent Development
Table 99. Pfizer Inc. Company Detail
Table 100. Pfizer Inc. Business Overview
Table 101. Pfizer Inc. Immuno-oncology Drugs Product
Table 102. Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 103. Pfizer Inc. Recent Development
Table 104. Sanofi S.A. Company Detail
Table 105. Sanofi S.A. Business Overview
Table 106. Sanofi S.A. Immuno-oncology Drugs Product
Table 107. Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 108. Sanofi S.A. Recent Development
Table 109. EMD Serono, Inc. Company Detail
Table 110. EMD Serono, Inc. Business Overview
Table 111. EMD Serono, Inc. Immuno-oncology Drugs Product
Table 112. EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 113. EMD Serono, Inc. Recent Development
Table 114. Gilead Sciences Inc. Company Detail
Table 115. Gilead Sciences Inc. Business Overview
Table 116. Gilead Sciences Inc. Immuno-oncology Drugs Product
Table 117. Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 118. Gilead Sciences Inc. Recent Development
Table 119. Prometheus Therapeutics & Diagnostics Company Detail
Table 120. Prometheus Therapeutics & Diagnostics Business Overview
Table 121. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product
Table 122. Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 123. Prometheus Therapeutics & Diagnostics Recent Development
Table 124. Aduro BioTech Company Detail
Table 125. Aduro BioTech Business Overview
Table 126. Aduro BioTech Immuno-oncology Drugs Product
Table 127. Aduro BioTech Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 128. Aduro BioTech Recent Development
Table 129. Galena Biopharma Company Detail
Table 130. Galena Biopharma Business Overview
Table 131. Galena Biopharma Immuno-oncology Drugs Product
Table 132. Galena Biopharma Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 133. Galena Biopharma Recent Development
Table 134. Bavarian Nordic Company Detail
Table 135. Bavarian Nordic Business Overview
Table 136. Bavarian Nordic Immuno-oncology Drugs Product
Table 137. Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 138. Bavarian Nordic Recent Development
Table 139. Celldex Therapeutics Company Detail
Table 140. Celldex Therapeutics Business Overview
Table 141. Celldex Therapeutics Immuno-oncology Drugs Product
Table 142. Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 143. Celldex Therapeutics Recent Development
Table 144. ImmunoCellular Therapeutics Company Detail
Table 145. ImmunoCellular Therapeutics Business Overview
Table 146. ImmunoCellular Therapeutics Immuno-oncology Drugs Product
Table 147. ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 148. ImmunoCellular Therapeutics Recent Development
Table 149. Incyte Company Detail
Table 150. Incyte Business Overview
Table 151. Incyte Immuno-oncology Drugs Product
Table 152. Incyte Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 153. Incyte Recent Development
Table 154. Dendreon Corporation Company Detail
Table 155. Dendreon Corporation Business Overview
Table 156. Dendreon Corporation Immuno-oncology Drugs Product
Table 157. Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 158. Dendreon Corporation Recent Development
Table 159. Agilent Technologies Inc. Company Detail
Table 160. Agilent Technologies Inc. Business Overview
Table 161. Agilent Technologies Inc. Immuno-oncology Drugs Product
Table 162. Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 163. Agilent Technologies Inc. Recent Development
Table 164. Agenus Inc. Company Detail
Table 165. Agenus Inc. Business Overview
Table 166. Agenus Inc. Immuno-oncology Drugs Product
Table 167. Agenus Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 168. Agenus Inc. Recent Development
Table 169. Enzo Biochem, Inc. Company Detail
Table 170. Enzo Biochem, Inc. Business Overview
Table 171. Enzo Biochem, Inc. Immuno-oncology Drugs Product
Table 172. Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 173. Enzo Biochem, Inc. Recent Development
Table 174. Lonza Group Company Detail
Table 175. Lonza Group Business Overview
Table 176. Lonza Group Immuno-oncology Drugs Product
Table 177. Lonza Group Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 178. Lonza Group Recent Development
Table 179. Bio-Rad Laboratories, Inc. Company Detail
Table 180. Bio-Rad Laboratories, Inc. Business Overview
Table 181. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product
Table 182. Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 183. Bio-Rad Laboratories, Inc. Recent Development
Table 184. Avantor, Inc. Company Detail
Table 185. Avantor, Inc. Business Overview
Table 186. Avantor, Inc. Immuno-oncology Drugs Product
Table 187. Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 188. Avantor, Inc. Recent Development
Table 189. Spring Bank Pharmaceuticals, Inc. Company Detail
Table 190. Spring Bank Pharmaceuticals, Inc. Business Overview
Table 191. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product
Table 192. Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 193. Spring Bank Pharmaceuticals, Inc. Recent Development
Table 194. Ferring Pharmaceuticals Company Detail
Table 195. Ferring Pharmaceuticals Business Overview
Table 196. Ferring Pharmaceuticals Immuno-oncology Drugs Product
Table 197. Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 198. Ferring Pharmaceuticals Recent Development
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immuno-oncology Drugs Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Immuno-oncology Drugs Market Share by Type: 2022 VS 2029
Figure 3. Immune Checkpoint Inhibitors Features
Figure 4. Immune System Modulators Features
Figure 5. Cancer Vaccines Features
Figure 6. Oncolytic Virus Features
Figure 7. Others Features
Figure 8. Global Immuno-oncology Drugs Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 9. Global Immuno-oncology Drugs Market Share by Application: 2022 VS 2029
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Ambulatory Surgical Centers Case Studies
Figure 13. Immuno-oncology Drugs Report Years Considered
Figure 14. Global Immuno-oncology Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Immuno-oncology Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Immuno-oncology Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Immuno-oncology Drugs Market Share by Players in 2022
Figure 18. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Immuno-oncology Drugs Revenue in 2022
Figure 20. North America Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 22. United States Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 26. Germany Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Immuno-oncology Drugs Market Share by Region (2018-2029)
Figure 34. China Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 42. Mexico Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 46. Turkey Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Amgen, Inc Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 49. AstraZeneca, Plc Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 51. Celgene Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 52. Eli Lilly and Company Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 53. Merck & Co. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 54. Hoffmann-La Roche AG Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 55. Johnson & Johnson Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 56. Novartis International AG Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 57. AbbVie, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 58. Pfizer Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 59. Sanofi S.A. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 60. EMD Serono, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 61. Gilead Sciences Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 62. Prometheus Therapeutics & Diagnostics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 63. Aduro BioTech Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 64. Galena Biopharma Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 65. Bavarian Nordic Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 66. Celldex Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 67. ImmunoCellular Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 68. Incyte Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 69. Dendreon Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 70. Agilent Technologies Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 71. Agenus Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 72. Enzo Biochem, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 73. Lonza Group Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 74. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 75. Avantor, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 76. Spring Bank Pharmaceuticals, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 77. Ferring Pharmaceuticals Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed